Devices

Baxter Recalls Mobile Lift Component

Baxter Healthcare has recalled (Class 1) a mobile lift component used in several patient lift devices due to the risk of improper attachment. The company says that the Q-link 13 component could allow for false latching of the quick-release hook used on sling bars and other accessories.

“The false latched component may initially bear weight but can loosen from the Q-link, resulting in a detachment and drop,” a recall notice says. “This could result in a critical injury from a patient fall. A caregiver may also be at risk of injury while attempting to stop a patient from falling.” To date, it says three serious injuries and one death have been reported due to the issue.

Baxter says the Q-Link 13 is an optional lift component that can be used in combination with mobile lifts when connected to a Quick-Release Hook for sling bars. The LikoScale adapter kit contains the Q-link 13 component and also has the potential for improper attachment. Mobile lifts are intended for transferring patients between bed and wheelchair, to and from toilets and bathtubs, and for lifting to and from the floor.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome